{"id":"continuous-release-dopamine-agonists","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Impulse control disorders"}]},"_chembl":{"chemblId":"CHEMBL1557","moleculeType":"Small molecule","molecularWeight":"189.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dopamine agonists work by directly binding to and activating dopamine receptors (D1, D2, or other subtypes) in the central nervous system. The continuous release formulation maintains steady-state dopamine receptor stimulation over extended periods, reducing dosing frequency and improving symptom control compared to immediate-release formulations. This approach is particularly useful in conditions where dopamine deficiency or dysfunction contributes to motor and non-motor symptoms.","oneSentence":"Continuous release dopamine agonists stimulate dopamine receptors in the brain to provide sustained therapeutic effects for movement and neurological disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:31.986Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT06052787","phase":"PHASE3","title":"Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-09-01","conditions":"Traumatic Brain Injury","enrollment":150},{"nctId":"NCT00465452","phase":"PHASE3","title":"Impact of Switching to Continuous Release Dopamine Agonists","status":"COMPLETED","sponsor":"University of Toledo","startDate":"2007-01","conditions":"Parkinson Disease","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ropinirole extended release"],"phase":"phase_3","status":"active","brandName":"Continuous Release Dopamine Agonists","genericName":"Continuous Release Dopamine Agonists","companyName":"University of Toledo","companyId":"university-of-toledo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continuous release dopamine agonists stimulate dopamine receptors in the brain to provide sustained therapeutic effects for movement and neurological disorders. Used for Parkinson's disease, Restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}